Varian invests in hydrogel tech to enhance prostate radiotherapy
This article was originally published in Clinica
Varian Medical Systems is investing $15m in Augmenix, a company developing a hydrogel product to improve efficacy in prostate radiotherapy. The deal gives Varian a minority stake and includes an option for the company to acquire Augmenix outright, subject to the achievement of certain milestones.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.